SAN FRANCISCO, Sept. 19, 2016 -- Hagens Berman Sobol Shapiro LLP alerts investors in Polaris Industries Inc. that the firm is investigating possible securities law violations by the Company and its officers.
To all investors in PII: If you purchased or otherwise acquired securities of PII between July 19, 2016 and September 11, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/PII
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On July 20, 2016, Polaris reported its 2016 second quarter results and provided fiscal year 2016 earnings guidance of $6 - $6.30 per share. In response, Polaris stock price rose approximately 9% to close at $95.03.
Then, on July 25, 2016 the Company voluntarily issued stop-ride/stop-sale advisory for its MY2016 RZR Turbo Off-Road Vehicles “due to a potential fire hazard.”
On September 12, 2016, Polaris slashed its fiscal year 2016 earnings guidance to $3.30 - $3.80 per share and explained: “the Company has experienced additional RZR thermal-related issues and was unable to sufficiently validate the initially identified RZR Turbo recall repair, necessitating a more complex and expensive repair solution [and] [a]s a result, the voluntary stop ride/stop sale notification issued on July 25, 2016 remained in place significantly longer than originally anticipated.” In response, Polaris stock price fell approximately 5% to close at $76.79.
SEC filings show that during August 2016 Polaris’ Chief Financial Officer and its President of the Off-Road Vehicles business together sold shares for total proceeds of over $623,000.
“We’re looking into when the Company and its senior officers knew the advisory should be extended relative to the dramatic 45% reduction in the low-end guidance and of course the propriety of insider sales,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Polaris Industries should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email. [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



